International
The Morning Science

What science found today

‹
 

Research2 sources

Multicenter characterization of enterocolitis associated with BCMA-directed CAR T cell therapy

Nature · By Lekha Mikkilineni ·

The Brief · written from 2 sources

  • Two Nature Medicine papers published 19 November 2026 characterise immune effector cell-associated enterocolitis after BCMA-directed CAR T cell therapy.
  • One study uses multimodal profiling of biopsy-confirmed cases after ciltacabtagene autoleucel, reporting that CAR T cell infiltrates are concentrated in the gut mucosa.
  • A larger multicenter case series reports that only 32% of patients who developed the enterocolitis had achieved disease response.

Why it matters

The studies describe a serious gastrointestinal complication of a widely used cancer immunotherapy, which helps clinicians recognise and characterise it in patients receiving BCMA CAR T cells.

Who’s affected

  • clinicians treating multiple myeloma with CAR T cell therapy
  • researchers in cell therapy and cancer immunology
  • #car t cells
  • #bcma
  • #enterocolitis
  • #immunotherapy
  • #multiple myeloma
  • #adverse events

Nature Medicine, Published online: 19 November 2026; doi:10.1038/s41591-026-04783-y In a large multicenter case series, only 32% of patients who developed immune effector cell-associated enterocolitis following treatment with BCMA-directed CAR T cells had achieved disease…

Timeline

  1. Both studies published online in Nature Medicine (doi:10.1038/s41591-026-04731-w and doi:10.1038/s41591-026-04783-y)

  2. nature.com

    Expansion and cytotoxicity of mucosal CAR + T cells in enterocolitis associated with BCMA CAR-T cell therapy

  3. nature.com

    Multicenter characterization of enterocolitis associated with BCMA-directed CAR T cell therapy

Full coverage · 2 sources

How do you feel about this?

0 Comments

    Multicenter characterization of enterocolitis associated with BCMA-directed CAR T cell therapy – The Morning Science